Skip to Content
About Abbott
Contact
United States | eng
Country Language
CARDIOVASCULAR
United States | eng
Country Language

CardioMEMS HF System

Remote Pulmonary Artery Pressure Monitor

CardioMEMS H System

About the CardioMEMS HF System

The CardioMEMS™ HF System allows clinicians to monitor heart failure patients’ pulmonary artery (PA) pressure for proactive and actionable heart failure (HF) management and treatment. With early indications of worsening heart failure, you can remotely make adjustments to care to help slow the progression of heart failure, often before patients feel symptoms.

Abbott’s CardioMEMS HF System is the leading remote monitoring platform for both HFpEF1 and HFrEF patients clinically proven to:

  • Aid physicians in preventing worsening heart failure2
  • Lower heart failure mortality rates3
  •  Improve quality of life for heart failure patients4
CardioMEMS HF System Product Information

CardioMEMS HF System Product Information

Indications

The CardioMEMS HF System is indicated for wirelessly measuring and monitoring pulmonary artery pressure and heart rate in NYHA Class II or III heart failure patients who either have been hospitalized for heart failure in the previous year and/or have elevated natriuretic peptides. The hemodynamic data are used by physicians for heart failure management with the goal of controlling pulmonary artery pressures and reducing heart failure hospitalizations.

Contraindications

The CardioMEMS HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant.

CardioMEMS HF System Clinical Evidence

Multiple clinical trials have evaluated the safety and effectiveness of the CardioMEMS HF System. For a deep dive into the clinical studies and trial designs, view more information on the Clinical Evidence.

Key Clinical Outcomes

Improved Survival4-6

Improved Survival

Reduction in Heart Failure Hospitalizations for HFpEF and HFrEF Patients7

Reduction in Heart Failure Hospitalizations for HFpEF Patients

Outstanding Safety Data

Outstanding Safety Data
Education and Training

More about the CardioMEMS HF System

For safe and reliable HF management with the CardioMEMS HF System, we provide comprehensive educational resources. The following are designed to help you and your patients better understand patient selection, implantation and care.

Education and Training

Reimbursement & Coding Highlights

Our full reimbursement resource documents provide information about coverage, coding and payment, denied claims and supporting documentation for the CardioMEMS HF System.

For the full resource list, visit Reimbursement & Coding for the CardioMEMS HF System.

Reimbursement & Coding

Reimbursement & Coding

Manuals & Resources

Manuals & Resources

Customer Service

Customer Service

References

  1. Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circulation: Heart Failure. 2014;7(6):935-944.
  2. Adamson PB. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. Current Heart Failure Reports. 2009;6:287-292.
  3. Abraham J, et al. Association of Ambulatory Hemodynamic Monitoring with Clinical Outcomes in a Concurrent Matched Cohort Analysis. JAMA Cardiology. 2019;4(6):556-563.
  4. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB, for the CHAMPION Trial Study Group. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. The Lancet. 2016;387(10017):453-461.
  5. Givertz MM, Stevenson LW, Costanzo MR, Bourge RC, Bauman JG, Ginn G, Abraham WT; CHAMPION Trial Investigators. Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2017.
  6. JoAnn Lindenfeld, on behalf of the GUIDE-HF, CHAMPION, and LAPTOPHF investigators. Longer Term Effects of Hemodynamic Monitoring on Outcomes: A Combined Data Analysis of patients with HFrEF in CHAMPION, GUIDE-HF, and LAPTOP-HF. Presented at THT Conference, Boston, MA, March 2023.
  7. Shavelle D. et al. Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure. Circulation: Heart Failure. Advance online publication. https://doi.org/10.1161/circheartfailure.119.006863.

MAT-2006904 v6.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
abbott logo

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-1900882 v13.0